A potential inflammatory biomarker for advanced endometrial cancer treated with lenvatinib plus pembrolizumab
Inflammatory biomarkers in endometrial LBC failed to predict the efficacy of LEN/PEM, while peripheral blood NLR score sampled prior to LEN/PEM potentially could be a significant predictor.
Authors
- Shintaro Yanazume (ORCID: https://orcid.org/0000-0003-2297-6648)
- Akihide Tanimoto (ORCID: https://orcid.org/0000-0001-7508-1624)
- Yusuke Kobayashi (ORCID: https://orcid.org/0000-0002-4503-2845)
- Ikumi Kitazono (ORCID: https://orcid.org/0000-0002-6746-6695)
- Hiroaki Kobayashi (ORCID: https://orcid.org/0000-0003-2491-2189)
- Ayumi Kozai
- Chikako Nagata
- Yukari Kirita
Institutions
- Kagoshima University (JP)
- Kagoshima University Hospital (JP)
Publication Details
- Journal
- Journal of obstetrics and gynaecology research
- Published
- 2024-12-23
- DOI
- https://doi.org/10.1111/jog.16182
- Citations
- 4
- Primary Topic
- Endometrial and Cervical Cancer Treatments
- Type
- article
- Field-Weighted Citation Impact
- 2.33